Aurora Cannabis Inc.
NASDAQ:ACBDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $289.28M
- Beta
- 1.34
- P/E (TTM)
- -3.2
- EPS (TTM)
- -$1.31
Volume 0.92M
Average 1.00M
ACB Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Aurora Cannabis Inc.NASDAQ: ACB
Cost of Revenue · Q4 FY2026 · quarter ended Mar 2026
Cost of revenue declines year over year
Q4 FY2026 cost of revenue of CA$19.94M fell 71.0% year over year, behind the -13.4% change in trailing-twelve-month cost of revenue. Sequentially, it fell 58.1% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.
Context
- Cost of revenue amounted to 94.8% of revenue in FY2026, up 49.4 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -71.0% toward the trailing-twelve-month pace of -13.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
CAD · from the income statement
- Latest · FY2026
- 304.67M CAD
- Year-over-year change
- +95.7%
- 4-year CAGR
- +11.1%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 304.67M | +95.7% |
| FY2025 | 2025-03-31 | 155.69M | +12.1% |
| FY2024 | 2024-03-31 | 138.82M | -33.6% |
| FY2023 | 2023-03-31 | 209.02M | +4.5% |
| FY2022 | 2022-06-30 | 200.11M | — |
Cost of Revenue vs competitors
How ACB compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -13.4% is the 6th highest of 9, against a peer median of +1.2%.
- Cost of revenue amounts to 43.4% of revenue for ACB, versus a peer median of 65.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | CA$553.94M CAD | +35.7% | +19.8% | 82.5% | |
| LTM Mar 2026 | CA$234.68M CAD | +23.9% | -0.9% | 75.1% | |
| LTM Mar 2026 | CA$176.48M CAD | +35.1% | — | 64.4% | |
| LTM Mar 2026 | CA$134.79M CAD | -13.4% | +13.4% | 43.4% | |
| LTM Mar 2026 | $93.03M USD | — | +7.0% | 68.8% | |
| LTM Mar 2026 | $36.44M USD | -53.4% | — | 94.2% | |
| LTM Mar 2026 | $30.96M USD | +10.1% | +28.2% | 14.1% | |
| LTM Mar 2026 | $27.87M USD | -7.8% | +4.2% | 66.7% | |
| LTM Mar 2026 | $1.98M USD | -86.0% | -44.1% | 23.7% | |
| LTM Mar 2026 | $1.39M USD | -97.6% | — | 0.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $63K USD | — | — | 0.6% |
| Peer median (excluding ACB) | — | +1.2% | +5.6% | 65.5% | |
Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 221.34M | 223.8M | 270.28M | 343.29M | 321.42M |
| Cost of Revenue | 200.11M | 209.02M | 138.82M | 155.69M | 304.67M |
| Gross Profit | 21.23M | 14.78M | 131.46M | 187.61M | 16.75M |
| Gross Margin | 9.6% | 6.6% | 48.6% | 54.6% | 5.2% |
| Research & Development | 10.39M | 5.77M | 3.57M | 3.68M | 6.01M |
| Selling, General & Admin | 188.99M | 170.48M | 156.88M | 166.47M | 173.95M |
| Operating Expenses | 252.67M | 221.98M | 177.91M | 182.66M | 179.96M |
| Depreciation & Amortization | 93.66M | 52.59M | 33.07M | 22.55M | 14.23M |
| EBITDA | (1.55B) | (135M) | (12.34M) | 51.35M | (148.99M) |
| EBITDA Margin | -702.4% | -60.3% | -4.6% | 15.0% | -46.4% |
| Operating Income | (231.45M) | (207.19M) | (46.45M) | 4.95M | (163.21M) |
| Operating Margin | -104.6% | -92.6% | -17.2% | 1.4% | -50.8% |
| Interest Income | 4.51M | 19M | 12.81M | 11.51M | 5.86M |
| Interest Expense | 71.81M | 39.46M | 14.19M | 8.42M | 1.81M |
| Other Income / Expenses | (1.49B) | (576.51M) | (13.15M) | 15.43M | 106.54M |
| Income Before Tax | (1.72B) | (783.7M) | (59.6M) | 20.38M | (56.67M) |
| Pre-Tax Margin | -777.1% | -350.2% | -22.1% | 5.9% | -17.6% |
| Income Tax Expense | (2.14M) | 16.55M | (554K) | 4.62M | 2.1M |
| Net Income | (1.72B) | (816.63M) | (69.33M) | 1.59M | (122.07M) |
| Net Margin | -776.0% | -364.9% | -25.6% | 0.5% | -38.0% |
| EPS (Basic) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| EPS (Diluted) | (79.92) | (8.17) | (1.28) | 0.03 | (2.15) |
| Weighted Avg Shares | 21.49M | 32.27M | 51.26M | 54.88M | 56.71M |
| Weighted Avg Shares (Diluted) | 21.49M | 32.27M | 51.26M | 55.75M | 56.71M |
Aurora Cannabis Inc.
NASDAQ:ACB
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.